Cargando…
The Role of Metformin in the Management of NAFLD
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Its prevalence ranges 10–24% in the general population, reaching 60–95% and 28–55% in obese and diabetic patients, respectively. Although the etiology of NAFLD is still unclear, several lines of evidences have indi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238361/ https://www.ncbi.nlm.nih.gov/pubmed/22194737 http://dx.doi.org/10.1155/2012/716404 |
_version_ | 1782218993447206912 |
---|---|
author | Mazza, Angela Fruci, Barbara Garinis, Giorgia Anna Giuliano, Stefania Malaguarnera, Roberta Belfiore, Antonino |
author_facet | Mazza, Angela Fruci, Barbara Garinis, Giorgia Anna Giuliano, Stefania Malaguarnera, Roberta Belfiore, Antonino |
author_sort | Mazza, Angela |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Its prevalence ranges 10–24% in the general population, reaching 60–95% and 28–55% in obese and diabetic patients, respectively. Although the etiology of NAFLD is still unclear, several lines of evidences have indicated a pathogenetic role of insulin resistance in this disorder. This concept has stimulated several clinical studies where antidiabetic drugs, such as insulin sensitizers including metformin, have been evaluated in insulin-resistant, NAFLD patients. These studies indicate that metformin might be of benefit in the treatment of NAFLD, also in nondiabetic patients, when associated to hypocaloric diet and weight control. However, the heterogeneity of these studies still prevents us from reaching firm conclusions about treatment guidelines. Moreover, metformin could have beneficial tissue-specific effects in NAFLD patients irrespective of its effects as insulin sensitizer. |
format | Online Article Text |
id | pubmed-3238361 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-32383612011-12-22 The Role of Metformin in the Management of NAFLD Mazza, Angela Fruci, Barbara Garinis, Giorgia Anna Giuliano, Stefania Malaguarnera, Roberta Belfiore, Antonino Exp Diabetes Res Review Article Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder worldwide. Its prevalence ranges 10–24% in the general population, reaching 60–95% and 28–55% in obese and diabetic patients, respectively. Although the etiology of NAFLD is still unclear, several lines of evidences have indicated a pathogenetic role of insulin resistance in this disorder. This concept has stimulated several clinical studies where antidiabetic drugs, such as insulin sensitizers including metformin, have been evaluated in insulin-resistant, NAFLD patients. These studies indicate that metformin might be of benefit in the treatment of NAFLD, also in nondiabetic patients, when associated to hypocaloric diet and weight control. However, the heterogeneity of these studies still prevents us from reaching firm conclusions about treatment guidelines. Moreover, metformin could have beneficial tissue-specific effects in NAFLD patients irrespective of its effects as insulin sensitizer. Hindawi Publishing Corporation 2012 2011-12-12 /pmc/articles/PMC3238361/ /pubmed/22194737 http://dx.doi.org/10.1155/2012/716404 Text en Copyright © 2012 Angela Mazza et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Mazza, Angela Fruci, Barbara Garinis, Giorgia Anna Giuliano, Stefania Malaguarnera, Roberta Belfiore, Antonino The Role of Metformin in the Management of NAFLD |
title | The Role of Metformin in the Management of NAFLD |
title_full | The Role of Metformin in the Management of NAFLD |
title_fullStr | The Role of Metformin in the Management of NAFLD |
title_full_unstemmed | The Role of Metformin in the Management of NAFLD |
title_short | The Role of Metformin in the Management of NAFLD |
title_sort | role of metformin in the management of nafld |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238361/ https://www.ncbi.nlm.nih.gov/pubmed/22194737 http://dx.doi.org/10.1155/2012/716404 |
work_keys_str_mv | AT mazzaangela theroleofmetformininthemanagementofnafld AT frucibarbara theroleofmetformininthemanagementofnafld AT garinisgiorgiaanna theroleofmetformininthemanagementofnafld AT giulianostefania theroleofmetformininthemanagementofnafld AT malaguarneraroberta theroleofmetformininthemanagementofnafld AT belfioreantonino theroleofmetformininthemanagementofnafld AT mazzaangela roleofmetformininthemanagementofnafld AT frucibarbara roleofmetformininthemanagementofnafld AT garinisgiorgiaanna roleofmetformininthemanagementofnafld AT giulianostefania roleofmetformininthemanagementofnafld AT malaguarneraroberta roleofmetformininthemanagementofnafld AT belfioreantonino roleofmetformininthemanagementofnafld |